Akshaya Patel, MD
Family Medicine · Louisville, KYNPI 1407963671
Payments from drug & device makers
Across 198 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$362
- Amgen$351
- Novo Nordisk$313
- AbbVie$284
- AstraZeneca$233
- GSK$153
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 28 | $362 |
| Amgen | 25 | $351 |
| Novo Nordisk | 26 | $313 |
| AbbVie(2 entities) | 17 | $284 |
| AstraZeneca | 12 | $233 |
| GSK | 11 | $153 |
| Pfizer | 10 | $146 |
| Sanofi-aventis U.S. LLC | 10 | $137 |
| Boehringer Ingelheim | 8 | $110 |
| Merck | 7 | $108 |
| Astellas Pharma US Inc | 6 | $78 |
| Amarin Pharma, Inc. | 5 | $76 |
| Bayer | 5 | $75 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Dynavax Technologies Corporation | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Johnson & Johnson | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$2,865 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $61,098 |
| FarxigaDapagliflozin Propanediol | 48 | $42,001 |
| EliquisApixaban | 46 | $39,856 |
| JardianceEmpagliflozin | 25 | $32,893 |
| MounjaroTirzepatide | 20 | $26,619 |
| JanuviaSitagliptin Phosphate | 25 | $25,279 |
| XareltoRivaroxaban | 11 | $14,777 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 25 | $13,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,367 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,875 |
| InvokanaCanagliflozin | 13 | $8,516 |
| Atorvastatin Calcium | 416 | $2,895 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,477 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 162 | $2,235 |
| Levothyroxine Sodium | 239 | $2,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $313 | $61,09851 claims |
| AstraZenecaFarxiga | $233 | $42,00148 claims |
| PfizerEliquis | $146 | $39,85646 claims |
| MerckJanuvia, Janumet Xr | $108 | $39,24850 claims |
| Boehringer IngelheimJardiance | $110 | $32,89325 claims |
| Lilly USA, LLCMounjaro | $362 | $26,61920 claims |
| Johnson & JohnsonXarelto, Invokana | $27 | $23,29324 claims |
| GSKTrelegy Ellipta | $153 | $9,36711 claims |
| AbbVieSynthroid | $284 | $1,02224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Louisville
- Christopher RhyneLouisville$1M
- Michael LovelaceLouisville$244K
- Suraj GathaniLouisville$69K
- Mandy WhittLouisville$38K
- Michael PendletonLouisville$29K
- Rajanbhai AminLouisville$26K
- James WrightLouisville$18K
- Rosenberg ReyesLouisville$18K
- Dennis GrayLouisville$14K
- Vincent LangLouisville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.